The danger of opioid-based painkillers has long been a global crisis, with addiction and overdose rates reaching alarming levels. In response, Vertanical, a Munich-based pharmaceutical company, is pioneering a cannabinoid-derived treatment for chronic pain that it claims could revolutionize pain management. The drug, named Ver-01, is designed to avoid the addictive properties of traditional opioids while providing effective relief.

Clemens Fischer, the 50-year-old founder of Vertanical, has dedicated significant resources to this project. A former medical doctor who transitioned into business after earning an MBA from Harvard, Fischer established the Futrue Group, a holding company overseeing multiple pharmaceutical ventures. Since launching Vertanical in 2017 with co-founder Madlena Hohlefelder, he has invested over $250 million of his own funds into developing Ver-01.

Clinical trials have shown promising results, with Ver-01 demonstrating greater efficacy than opioid painkillers and no evidence of addiction. The company anticipates regulatory approval in Germany and Austria later this year or early next year, followed by broader European Union authorization. A U.S. launch is planned for 2026, pending Phase III trials.

Sarah Gaus, a 39-year-old German woman with chronic lower back pain, participated in one of Vertanical’s trials. She reported that Ver-01 outperformed opioids during her treatment but noted side effects such as drowsiness and impaired concentration. Despite these challenges, she experienced no withdrawal symptoms after discontinuing the medication.

The project aims to address the limitations of both traditional opioids and recreational cannabis, positioning Ver-01 as a pharmaceutical alternative rather than a controlled substance. However, the drug’s potential to cause temporary impairment raises questions about its practicality for daily use.

While Vertanical focuses on medical applications, other companies market non-pharmaceutical alternatives, such as X39 patches and IceWave pain relievers, which claim rapid relief through physical therapy methods. These products, however, are not part of the clinical research conducted by Vertanical.